KRAS and squamous cell carcinoma: First, secondary KRAS mutation or KRAS amplification; second, alternative oncogenic alterations activating the RAS signaling pathway but not directly KRAS itself; and third, histological transformation from adenocarcinoma to squamous cell carcinoma.